Decentralized Clinical Trials Software’s in 2023: What to Expect

by Rajesh Pothula    Contributor        Biopharma insight

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   1453    Comments
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Healthcare technology is advancing at an unprecedented pace, and the clinical trials industry is no exception. The past few years have seen a steady rise in the adoption of decentralized clinical trials (DCTs) as an alternative to traditional clinical trials, and this trend is expected to continue in 2023 and beyond.

Decentralized clinical trials have gained popularity due to their ability to improve patient access, reduce costs, and accelerate study timelines. DCTs leverage digital technologies to enable patients to participate in clinical trials from the comfort of their own homes or nearby medical facilities, instead of having to travel to a centralized trial site. This has been particularly important during the COVID-19 pandemic, as traditional clinical trials were significantly impacted by lockdowns and social distancing measures.

With the growing need for accelerated drug development, traditional site-centric clinical trial models have evolved to handle consumer requirements during unforeseen events. According to recent data published by the Global data Pharma Intelligence Center, decentralized or remote clinical trials have successfully brought research closer to the patients, with an overall increase of 1.3% of all trials in 2011 to 2.5% in 2020

However, as the adoption of DCTs increases, so do the challenges associated with implementing and managing them. One of the key challenges is the need for specialized software that can facilitate the remote collection, management, and analysis of clinical trial data.

In this article, we will explore the current state of decentralized clinical trials software and what we can expect to see in 2023.

Image: Clinion Software dashboard. 

 

The Current State of Decentralized Clinical Trials Software

The software landscape for decentralized clinical trials is still relatively new and fragmented, with a variety of different vendors and platforms available. Some of the major players in the market include 

 

Medable: Medable is a cloud-based platform that enables remote patient monitoring, decentralized trial management, and virtual trial conduct. The platform provides a range of features, including eConsent, ePRO, and telemedicine capabilities.

Pros:

  • Medable's platform offers a wide range of features for decentralized trial management, including eConsent, ePRO, and telemedicine capabilities.
  • The platform is cloud-based, making it easy for trial teams to access and manage data from anywhere.
  • Medable has a strong focus on patient engagement and has developed tools to help patients participate in clinical trials remotely.

Cons:

  • Some users have reported that the platform can be complex to set up and use, particularly for smaller trial teams.
  • Medable's pricing can be expensive, especially for small CRO’s.

 

Medrio: Medrio is another key player in the decentralized clinical trial space. 

It is a cloud-based electronic data capture (EDC) and eSource platform that enables remote data capture and monitoring.

Continue reading

This content available exclusively for BPT Mebmers

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments